Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Deferred Tax Liability: 2022-2024

Historic Non-Current Deferred Tax Liability for Crinetics Pharmaceuticals (CRNX) over the last 3 years, with Dec 2024 value amounting to $9.8 million.

  • Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability fell 0.49% to $9.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $9.8 million, marking a year-over-year decrease of 0.49%. This contributed to the annual value of $9.8 million for FY2024, which is 0.49% down from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Non-Current Deferred Tax Liability stood at $9.8 million for FY2024, which was down 0.49% from $9.8 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability ranged from a high of $9.8 million in FY2023 and a low of $453,000 during FY2022.
  • Over the past 3 years, Crinetics Pharmaceuticals' median Non-Current Deferred Tax Liability value was $9.8 million (recorded in 2024), while the average stood at $6.7 million.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability soared by 2,063.13% in 2023 and then dropped by 0.49% in 2024.
  • Yearly analysis of 3 years shows Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability stood at $453,000 in 2022, then surged by 2,063.13% to $9.8 million in 2023, then fell by 0.49% to $9.8 million in 2024.